Status:
COMPLETED
Efficacy and Safety of Apremilast in Psoriasis
Lead Sponsor:
Ghurki Trust and Teaching Hospital
Conditions:
Psoriasis
Eligibility:
All Genders
18-59 years
Phase:
PHASE4
Brief Summary
Psoriasis is a long standing inflammatory, autoinflammatory disease linked with many comorbidities. Patients with moderate to severe plaque psoriasis can be managed with topical as well as systemic me...
Eligibility Criteria
Inclusion
- Diagnosed patients of chronic plaque psoriasis
- patients applicant for oral or parenteral treatments and for light therapy
- patients not responding to topical treatments
Exclusion
- Patients who show hypersensitive reactions to apremilast to any of its inactive component
- Pregnancy
- Lactating mothers
Key Trial Info
Start Date :
March 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 10 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06032858
Start Date
March 6 2022
End Date
August 10 2023
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ghurki Hospital
Lahore, Punjab Province, Pakistan, 54000